BIOEX Stock Overview
Develops and commercializes a bio-based extraction platform technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bioextrax AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.90 |
| 52 Week High | SEK 4.94 |
| 52 Week Low | SEK 1.54 |
| Beta | 2.7 |
| 11 Month Change | -18.54% |
| 3 Month Change | -2.85% |
| 1 Year Change | -31.28% |
| 33 Year Change | -91.94% |
| 5 Year Change | n/a |
| Change since IPO | -27.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOEX | SE Machinery | SE Market | |
|---|---|---|---|
| 7D | -12.1% | -6.9% | -6.7% |
| 1Y | -31.3% | 8.9% | 9.9% |
Return vs Industry: BIOEX underperformed the Swedish Machinery industry which returned 11.1% over the past year.
Return vs Market: BIOEX underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| BIOEX volatility | |
|---|---|
| BIOEX Average Weekly Movement | 11.5% |
| Machinery Industry Average Movement | 5.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BIOEX's share price has been volatile over the past 3 months.
Volatility Over Time: BIOEX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 13 | Edvard Hall | www.bioextrax.com |
Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. It harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids from bacteria. The company was incorporated in 2014 and is based in Lund, Sweden.
Bioextrax AB (publ) Fundamentals Summary
| BIOEX fundamental statistics | |
|---|---|
| Market cap | SEK 99.92m |
| Earnings (TTM) | -SEK 22.16m |
| Revenue (TTM) | SEK 2.15m |
46.4x
P/S Ratio-4.5x
P/E RatioIs BIOEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOEX income statement (TTM) | |
|---|---|
| Revenue | SEK 2.15m |
| Cost of Revenue | SEK 1.57m |
| Gross Profit | SEK 584.00k |
| Other Expenses | SEK 22.74m |
| Earnings | -SEK 22.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 27.12% |
| Net Profit Margin | -1,029.12% |
| Debt/Equity Ratio | 0% |
How did BIOEX perform over the long term?
See historical performance and comparison